Literature DB >> 16928859

Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers.

Julie K Staley1, Suchitra Krishnan-Sarin, Kelly P Cosgrove, Erica Krantzler, Erin Frohlich, Edward Perry, Joel A Dubin, Kristina Estok, Eric Brenner, Ronald M Baldwin, Gilles D Tamagnan, John P Seibyl, Peter Jatlow, Marina R Picciotto, Edythe D London, Stephanie O'Malley, Christopher H van Dyck.   

Abstract

Nicotine, the addictive chemical in tobacco smoke, initiates its actions in brain through nicotinic acetylcholine receptors (nAChRs). In particular, nAChRs containing beta2-subunits (beta2*-nAChRs) the most prevalent subtype, mediate the reinforcing properties of nicotine. We hypothesized that abnormal numbers of beta2*-nAChRs during early abstinence contribute to the perpetuation of addiction to tobacco smoking. Using molecular imaging, specifically single-photon emission computed tomography with the nAChR agonist radiotracer [123I]5-IA-85380 ([123I]5-IA), we imaged beta2*-nAChR availability in human smokers. First, using nonhuman primates treated chronically with nicotine, we estimated the time interval necessary for smokers to abstain from smoking so that residual nicotine would not interfere with [123I]5-IA binding to the beta2*-nAChR as approximately 7 d. Thus, we imaged human smokers at 6.8 +/- 1.9 d (mean +/- SD) of abstinence. Abstinence was confirmed by daily assessments of urinary cotinine and expired carbon monoxide levels. In smokers, [123I]5-IA uptake was significantly higher throughout the cerebral cortex (26-36%) and in the striatum (27%) than in nonsmokers, suggesting higher beta2*-nAChR in recently abstinent smokers. Beta2*-nAChR availability in recently abstinent smokers correlated with the days since last cigarette and the urge to smoke to relieve withdrawal symptoms but not the severity of nicotine dependence, severity of nicotine withdrawal, or the desire to smoke. Higher brain beta2*-nAChR during early abstinence indicates that, when smokers quit smoking, they do so in the face of a significant increase in the receptors normally activated by nicotine. Greater beta2*-nAChR availability during early abstinence may impact the ability of smokers to maintain abstinence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16928859      PMCID: PMC6674379          DOI: 10.1523/JNEUROSCI.0546-06.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  52 in total

1.  SPECT imaging with the D(4) receptor antagonist L-750,667 in nonhuman primate brain.

Authors:  J K Staley; G Tamagnan; R M Baldwin; M Fujita; M S Al Tikriti; L Eshima; J Thornback; D Roe; L Lu; J P Seibyl; R B Innis
Journal:  Nucl Med Biol       Date:  2000-08       Impact factor: 2.408

2.  Automated Talairach atlas labels for functional brain mapping.

Authors:  J L Lancaster; M G Woldorff; L M Parsons; M Liotti; C S Freitas; L Rainey; P V Kochunov; D Nickerson; S A Mikiten; P T Fox
Journal:  Hum Brain Mapp       Date:  2000-07       Impact factor: 5.038

3.  Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon.

Authors:  J L Musachio; V L Villemagne; U A Scheffel; R F Dannals; A S Dogan; F Yokoi; D F Wong
Journal:  Nucl Med Biol       Date:  1999-02       Impact factor: 2.408

4.  Radiosynthesis and preliminary evaluation of 5-[123/125I]iodo-3-(2(S)-azetidinylmethoxy)pyridine: a radioligand for nicotinic acetylcholine receptors.

Authors:  A G Horti; A O Koren; K S Lee; A G Mukhin; D B Vaupel; A S Kimes; M Stratton; E D London
Journal:  Nucl Med Biol       Date:  1999-02       Impact factor: 2.408

5.  Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function.

Authors:  B Buisson; D Bertrand
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

6.  Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk.

Authors:  R F Tyndale; E M Sellers
Journal:  Drug Metab Dispos       Date:  2001-04       Impact factor: 3.922

7.  Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies.

Authors:  D C Perry; M I Dávila-García; C A Stockmeier; K J Kellar
Journal:  J Pharmacol Exp Ther       Date:  1999-06       Impact factor: 4.030

8.  [(3)H]Nicotine binding in peripheral blood cells of smokers is correlated with the number of cigarettes smoked per day.

Authors:  K Benhammou; M Lee; M Strook; B Sullivan; J Logel; K Raschen; C Gotti; S Leonard
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

9.  Measurement of plasma metabolites of (S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates.

Authors:  Sami S Zoghbi; Gilles Tamagnan; Masahiro Fujita; Ronald M Baldwin; Mohammed S Al-Tikriti; Louis Amici; John P Seibyl; Robert B Innis
Journal:  Nucl Med Biol       Date:  2001-01       Impact factor: 2.408

10.  5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors.

Authors:  A G Mukhin; D Gündisch; A G Horti; A O Koren; G Tamagnan; A S Kimes; J Chambers; D B Vaupel; S L King; M R Picciotto; R B Innis; E D London
Journal:  Mol Pharmacol       Date:  2000-03       Impact factor: 4.436

View more
  107 in total

1.  Nicotinic acetylcholine receptor expression on B-lymphoblasts of healthy versus schizophrenic subjects stratified for smoking: [3H]-nicotine binding is decreased in schizophrenia and correlates with negative symptoms.

Authors:  Christian Luckhaus; Uwe Henning; Stefano Ferrea; Francesco Musso; Arian Mobascher; Georg Winterer
Journal:  J Neural Transm (Vienna)       Date:  2011-12-11       Impact factor: 3.575

2.  Sex differences in availability of β2*-nicotinic acetylcholine receptors in recently abstinent tobacco smokers.

Authors:  Kelly P Cosgrove; Irina Esterlis; Sherry A McKee; Frederic Bois; John P Seibyl; Carolyn M Mazure; Suchitra Krishnan-Sarin; Julie K Staley; Marina R Picciotto; Stephanie S O'Malley
Journal:  Arch Gen Psychiatry       Date:  2012-04

Review 3.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

4.  Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder.

Authors:  Aybala Saricicek; Irina Esterlis; Kathleen H Maloney; Yann S Mineur; Barbara M Ruf; Anjana Muralidharan; Jason I Chen; Kelly P Cosgrove; Rebecca Kerestes; Subroto Ghose; Carol A Tamminga; Brian Pittman; Frederic Bois; Gilles Tamagnan; John Seibyl; Marina R Picciotto; Julie K Staley; Zubin Bhagwagar
Journal:  Am J Psychiatry       Date:  2012-08       Impact factor: 18.112

5.  Quantitative Molecular Imaging of Neuronal Nicotinic Acetylcholine Receptors in the Human Brain with A-85380 Radiotracers.

Authors:  Shahrdad Lotfipour; Mark Mandelkern; Arthur L Brody
Journal:  Curr Med Imaging Rev       Date:  2011-05-01

6.  Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism.

Authors:  Jacob G Dubroff; Robert K Doot; Mary Falcone; Robert A Schnoll; Riju Ray; Rachel F Tyndale; Arthur L Brody; Catherine Hou; Alexander Schmitz; Caryn Lerman
Journal:  J Nucl Med       Date:  2015-08-13       Impact factor: 10.057

7.  The duration of nicotine withdrawal-associated deficits in contextual fear conditioning parallels changes in hippocampal high affinity nicotinic acetylcholine receptor upregulation.

Authors:  Thomas J Gould; George S Portugal; Jessica M André; Matthew P Tadman; Michael J Marks; Justin W Kenney; Emre Yildirim; Michael Adoff
Journal:  Neuropharmacology       Date:  2012-01-21       Impact factor: 5.250

8.  Long-term upregulation of protein kinase A and adenylate cyclase levels in human smokers.

Authors:  Bruce T Hope; Deepti Nagarkar; Sherry Leonard; Roy A Wise
Journal:  J Neurosci       Date:  2007-02-21       Impact factor: 6.167

9.  Smoking and Neuroimaging: A Review.

Authors:  Hedy Kober; Cameron M Deleone
Journal:  Curr Cardiovasc Risk Rep       Date:  2011-12-01

10.  Single photon emission computed tomography experience with (S)-5-[(123)I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers.

Authors:  James Robert Brasić; Yun Zhou; John L Musachio; John Hilton; Hong Fan; Andrew Crabb; Christopher J Endres; Melvin J Reinhardt; Ahmet S Dogan; Mohab Alexander; Olivier Rousset; Marika A Maris; Jeffrey Galecki; Ayon Nandi; Dean F Wong
Journal:  Synapse       Date:  2009-04       Impact factor: 2.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.